Arthritis Monoclonal Antibodies  Market Report

Global Arthritis Monoclonal Antibodies Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：199
  • REPORT CODE：GMM857418
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Arthritis Monoclonal Antibodies market report explains the definition, types, applications, major countries, and major players of the Arthritis Monoclonal Antibodies market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Novartis

    • Pfizer Inc

    • Mylan

    • GSK

    • AbbVie Inc

    • AstraZeneca PLC

    • Johnson & Johnson(Janssen)

    • Genentech

    • F Hoffmann-La Roche Ltd

    By Type:

    • Remicade

    • Humira

    • Enbrel

    • Rituxan

    • Orencia

    • Actemra

    • Simponi

    • Cimzia

    By End-User:

    • Rheumatoid Arthritis

    • Osteoarthritis

    • Psoriatic Arthritis

    • Ankylosing Spondylitis

    • Fibromyalgia

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Arthritis Monoclonal Antibodies Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Arthritis Monoclonal Antibodies Outlook to 2028- Original Forecasts

    • 2.2 Arthritis Monoclonal Antibodies Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Arthritis Monoclonal Antibodies Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Arthritis Monoclonal Antibodies Market- Recent Developments

    • 6.1 Arthritis Monoclonal Antibodies Market News and Developments

    • 6.2 Arthritis Monoclonal Antibodies Market Deals Landscape

    7 Arthritis Monoclonal Antibodies Raw Materials and Cost Structure Analysis

    • 7.1 Arthritis Monoclonal Antibodies Key Raw Materials

    • 7.2 Arthritis Monoclonal Antibodies Price Trend of Key Raw Materials

    • 7.3 Arthritis Monoclonal Antibodies Key Suppliers of Raw Materials

    • 7.4 Arthritis Monoclonal Antibodies Market Concentration Rate of Raw Materials

    • 7.5 Arthritis Monoclonal Antibodies Cost Structure Analysis

      • 7.5.1 Arthritis Monoclonal Antibodies Raw Materials Analysis

      • 7.5.2 Arthritis Monoclonal Antibodies Labor Cost Analysis

      • 7.5.3 Arthritis Monoclonal Antibodies Manufacturing Expenses Analysis

    8 Global Arthritis Monoclonal Antibodies Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Arthritis Monoclonal Antibodies Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Arthritis Monoclonal Antibodies Export by Region (Top 10 Countries) (2017-2028)

    9 Global Arthritis Monoclonal Antibodies Market Outlook by Types and Applications to 2022

    • 9.1 Global Arthritis Monoclonal Antibodies Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Remicade Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Humira Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Enbrel Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Rituxan Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Orencia Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Actemra Consumption and Growth Rate (2017-2022)

      • 9.1.7 Global Simponi Consumption and Growth Rate (2017-2022)

      • 9.1.8 Global Cimzia Consumption and Growth Rate (2017-2022)

    • 9.2 Global Arthritis Monoclonal Antibodies Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Rheumatoid Arthritis Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Osteoarthritis Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Psoriatic Arthritis Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Ankylosing Spondylitis Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Fibromyalgia Consumption and Growth Rate (2017-2022)

      • 9.2.6 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Arthritis Monoclonal Antibodies Market Analysis and Outlook till 2022

    • 10.1 Global Arthritis Monoclonal Antibodies Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.2.2 Canada Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.2.3 Mexico Arthritis Monoclonal Antibodies Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.2 UK Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.3 Spain Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.4 Belgium Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.5 France Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.6 Italy Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.7 Denmark Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.8 Finland Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.9 Norway Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.10 Sweden Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.11 Poland Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.12 Russia Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.3.13 Turkey Arthritis Monoclonal Antibodies Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.2 Japan Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.3 India Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.4 South Korea Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.5 Pakistan Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.6 Bangladesh Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.7 Indonesia Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.8 Thailand Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.9 Singapore Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.10 Malaysia Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.11 Philippines Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.4.12 Vietnam Arthritis Monoclonal Antibodies Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.5.2 Colombia Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.5.3 Chile Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.5.4 Argentina Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.5.5 Venezuela Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.5.6 Peru Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.5.7 Puerto Rico Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.5.8 Ecuador Arthritis Monoclonal Antibodies Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.6.2 Kuwait Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.6.3 Oman Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.6.4 Qatar Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Arthritis Monoclonal Antibodies Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.7.2 South Africa Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.7.3 Egypt Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.7.4 Algeria Arthritis Monoclonal Antibodies Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Arthritis Monoclonal Antibodies Consumption (2017-2022)

      • 10.8.2 New Zealand Arthritis Monoclonal Antibodies Consumption (2017-2022)

    11 Global Arthritis Monoclonal Antibodies Competitive Analysis

    • 11.1 Novartis

      • 11.1.1 Novartis Company Details

      • 11.1.2 Novartis Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Novartis Arthritis Monoclonal Antibodies Main Business and Markets Served

      • 11.1.4 Novartis Arthritis Monoclonal Antibodies Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Pfizer Inc

      • 11.2.1 Pfizer Inc Company Details

      • 11.2.2 Pfizer Inc Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Pfizer Inc Arthritis Monoclonal Antibodies Main Business and Markets Served

      • 11.2.4 Pfizer Inc Arthritis Monoclonal Antibodies Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Mylan

      • 11.3.1 Mylan Company Details

      • 11.3.2 Mylan Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Mylan Arthritis Monoclonal Antibodies Main Business and Markets Served

      • 11.3.4 Mylan Arthritis Monoclonal Antibodies Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 GSK

      • 11.4.1 GSK Company Details

      • 11.4.2 GSK Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 GSK Arthritis Monoclonal Antibodies Main Business and Markets Served

      • 11.4.4 GSK Arthritis Monoclonal Antibodies Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 AbbVie Inc

      • 11.5.1 AbbVie Inc Company Details

      • 11.5.2 AbbVie Inc Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 AbbVie Inc Arthritis Monoclonal Antibodies Main Business and Markets Served

      • 11.5.4 AbbVie Inc Arthritis Monoclonal Antibodies Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 AstraZeneca PLC

      • 11.6.1 AstraZeneca PLC Company Details

      • 11.6.2 AstraZeneca PLC Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 AstraZeneca PLC Arthritis Monoclonal Antibodies Main Business and Markets Served

      • 11.6.4 AstraZeneca PLC Arthritis Monoclonal Antibodies Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Johnson & Johnson(Janssen)

      • 11.7.1 Johnson & Johnson(Janssen) Company Details

      • 11.7.2 Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Main Business and Markets Served

      • 11.7.4 Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Genentech

      • 11.8.1 Genentech Company Details

      • 11.8.2 Genentech Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Genentech Arthritis Monoclonal Antibodies Main Business and Markets Served

      • 11.8.4 Genentech Arthritis Monoclonal Antibodies Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 F Hoffmann-La Roche Ltd

      • 11.9.1 F Hoffmann-La Roche Ltd Company Details

      • 11.9.2 F Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 F Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Main Business and Markets Served

      • 11.9.4 F Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    12 Global Arthritis Monoclonal Antibodies Market Outlook by Types and Applications to 2028

    • 12.1 Global Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Remicade Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Humira Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Enbrel Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Rituxan Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Orencia Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.6 Global Actemra Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.7 Global Simponi Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.8 Global Cimzia Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Rheumatoid Arthritis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Osteoarthritis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Psoriatic Arthritis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Ankylosing Spondylitis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.5 Global Fibromyalgia Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.6 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Arthritis Monoclonal Antibodies Market Analysis and Outlook to 2028

    • 13.1 Global Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.2.2 Canada Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.2 UK Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.3 Spain Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.5 France Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.6 Italy Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.8 Finland Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.9 Norway Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.11 Poland Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.12 Russia Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.2 Japan Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.3 India Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.5.3 Chile Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.5.6 Peru Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.6.3 Oman Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Arthritis Monoclonal Antibodies Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Arthritis Monoclonal Antibodies

    • Figure of Arthritis Monoclonal Antibodies Picture

    • Table Global Arthritis Monoclonal Antibodies Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Arthritis Monoclonal Antibodies Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Remicade Consumption and Growth Rate (2017-2022)

    • Figure Global Humira Consumption and Growth Rate (2017-2022)

    • Figure Global Enbrel Consumption and Growth Rate (2017-2022)

    • Figure Global Rituxan Consumption and Growth Rate (2017-2022)

    • Figure Global Orencia Consumption and Growth Rate (2017-2022)

    • Figure Global Actemra Consumption and Growth Rate (2017-2022)

    • Figure Global Simponi Consumption and Growth Rate (2017-2022)

    • Figure Global Cimzia Consumption and Growth Rate (2017-2022)

    • Figure Global Rheumatoid Arthritis Consumption and Growth Rate (2017-2022)

    • Figure Global Osteoarthritis Consumption and Growth Rate (2017-2022)

    • Figure Global Psoriatic Arthritis Consumption and Growth Rate (2017-2022)

    • Figure Global Ankylosing Spondylitis Consumption and Growth Rate (2017-2022)

    • Figure Global Fibromyalgia Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Arthritis Monoclonal Antibodies Consumption by Country (2017-2022)

    • Table North America Arthritis Monoclonal Antibodies Consumption by Country (2017-2022)

    • Figure United States Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Canada Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Mexico Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Table Europe Arthritis Monoclonal Antibodies Consumption by Country (2017-2022)

    • Figure Germany Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure UK Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Spain Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Belgium Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure France Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Italy Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Denmark Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Finland Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Norway Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Sweden Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Poland Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Russia Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Turkey Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Table APAC Arthritis Monoclonal Antibodies Consumption by Country (2017-2022)

    • Figure China Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Japan Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure India Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure South Korea Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Thailand Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Singapore Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Philippines Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Table South America Arthritis Monoclonal Antibodies Consumption by Country (2017-2022)

    • Figure Brazil Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Colombia Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Chile Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Argentina Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Peru Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Table GCC Arthritis Monoclonal Antibodies Consumption by Country (2017-2022)

    • Figure Bahrain Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Oman Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Qatar Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Table Africa Arthritis Monoclonal Antibodies Consumption by Country (2017-2022)

    • Figure Nigeria Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure South Africa Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Egypt Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Algeria Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Table Oceania Arthritis Monoclonal Antibodies Consumption by Country (2017-2022)

    • Figure Australia Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Arthritis Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Table Novartis Company Details

    • Table Novartis Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Arthritis Monoclonal Antibodies Main Business and Markets Served

    • Table Novartis Arthritis Monoclonal Antibodies Product Portfolio

    • Table Pfizer Inc Company Details

    • Table Pfizer Inc Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Arthritis Monoclonal Antibodies Main Business and Markets Served

    • Table Pfizer Inc Arthritis Monoclonal Antibodies Product Portfolio

    • Table Mylan Company Details

    • Table Mylan Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Arthritis Monoclonal Antibodies Main Business and Markets Served

    • Table Mylan Arthritis Monoclonal Antibodies Product Portfolio

    • Table GSK Company Details

    • Table GSK Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK Arthritis Monoclonal Antibodies Main Business and Markets Served

    • Table GSK Arthritis Monoclonal Antibodies Product Portfolio

    • Table AbbVie Inc Company Details

    • Table AbbVie Inc Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table AbbVie Inc Arthritis Monoclonal Antibodies Main Business and Markets Served

    • Table AbbVie Inc Arthritis Monoclonal Antibodies Product Portfolio

    • Table AstraZeneca PLC Company Details

    • Table AstraZeneca PLC Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca PLC Arthritis Monoclonal Antibodies Main Business and Markets Served

    • Table AstraZeneca PLC Arthritis Monoclonal Antibodies Product Portfolio

    • Table Johnson & Johnson(Janssen) Company Details

    • Table Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Main Business and Markets Served

    • Table Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Product Portfolio

    • Table Genentech Company Details

    • Table Genentech Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genentech Arthritis Monoclonal Antibodies Main Business and Markets Served

    • Table Genentech Arthritis Monoclonal Antibodies Product Portfolio

    • Table F Hoffmann-La Roche Ltd Company Details

    • Table F Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Main Business and Markets Served

    • Table F Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Product Portfolio

    • Figure Global Remicade Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Humira Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Enbrel Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Rituxan Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Orencia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Actemra Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Simponi Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cimzia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Rheumatoid Arthritis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Osteoarthritis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Psoriatic Arthritis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ankylosing Spondylitis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Fibromyalgia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Arthritis Monoclonal Antibodies Consumption Forecast by Country (2022-2028)

    • Table North America Arthritis Monoclonal Antibodies Consumption Forecast by Country (2022-2028)

    • Figure United States Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Arthritis Monoclonal Antibodies Consumption Forecast by Country (2022-2028)

    • Figure Germany Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Arthritis Monoclonal Antibodies Consumption Forecast by Country (2022-2028)

    • Figure China Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Arthritis Monoclonal Antibodies Consumption Forecast by Country (2022-2028)

    • Figure Brazil Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Arthritis Monoclonal Antibodies Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Arthritis Monoclonal Antibodies Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Arthritis Monoclonal Antibodies Consumption Forecast by Country (2022-2028)

    • Figure Australia Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Arthritis Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US